Clinical trial

Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis

NCT00269867

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Infliximab 3 mg/kg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Infliximab 10 mg/kg Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date1997-03-01

PhasePHASE3

Conditions

Rheumatoid Arthritisverified · MONDO: rheumatoid arthritis

Interventions

PlaceboDRUG

Infliximab 3 mg/kgDRUG

Infliximab 10 mg/kgDRUG

Sponsors & collaborators

Centocor, Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00269867 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.